Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

OTC Hangover Remedy Safety On Tap For FDA Advisory Committees

Executive Summary

CDER schedules an NDAC and DSRMAC joint meeting while also negotiating with industry stakeholders on a potential proposal for a user fee program to support FDA’s work on finalizing monographs or amending monographs with additional ingredients or indications.

You may also be interested in...



FDA Should Call Last Round For OTC Hangover Indication, Cmte. Suggests

Comments from the Nonprescription Drug and the Drug Safety and Risk Management advisory committees during a joint meeting could push US FDA toward pulling the plug on hangover as a monograph indication.

FDA Should Call Last Round For OTC Hangover Indication, Cmte. Suggests

Comments from the Nonprescription Drug and the Drug Safety and Risk Management advisory committees during a joint meeting could push US FDA toward pulling the plug on hangover as a monograph indication.

Recent And Upcoming FDA Advisory Committee Meetings

Recent and upcoming US FDA advisory committee meetings and a summary of topics covered.

Related Content

Topics

UsernamePublicRestriction

Register

LL1133951

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel